Business Context and Reporting Period
Company: pSivida Corp. (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2011
Event: Entry into a Material Definitive Agreement with Pfizer Inc.
Key Financial Metrics and Transaction Terms
This filing details a strategic collaboration rather than standard periodic financial results. Key financial terms of the Amended and Restated Collaborative Research and License Agreement include:
- Upfront Payment: $2.3 million in cash from Pfizer to pSivida.
- Total Potential Consideration: Up to $168.8 million plus royalties.
- Option Fee: $20 million payable by Pfizer upon completion of Phase II clinical trials to acquire an exclusive worldwide license.
- Milestone Payments: Up to $146.5 million in development, regulatory, and commercial milestones if the option is exercised.
- Royalties: Double-digit royalties based on net sales of the Product.
- Development Costs: pSivida bears the expense for development through Phase II clinical trials.
Note: The filing text does not provide clear values for the company's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Structure
The Restated Agreement amends and restates the Original Agreement dated April 3, 2007. Material changes include:
- IP Rights: pSivida regains all rights to its intellectual property in ophthalmic applications previously included in the Original Agreement, except for rights granted under the Restated Agreement.
- Product Scope: Focuses on a sustained release bioerodible implant delivering latanoprost for ophthalmic disease (excluding Uveitis).
- Development Path: pSivida must use commercially reasonable efforts to develop the Product for at least one year and through Phase II trials. Pfizer provides technical assistance.
- Termination Rights: Pfizer may terminate at its sole discretion on 60 days' notice. If Pfizer terminates or pSivida terminates for material breach, pSivida retains the right to develop and commercialize the Product.
Outlook, Risks, and Contingencies
Outlook and Status: An investigator-sponsored Phase I/II dose-escalating clinical study assessing safety and efficacy in patients with elevated intraocular pressure is currently underway.
Contingencies:
- Option Exercise: Future revenue is contingent on Pfizer exercising its option after Phase II trials. If Pfizer does not exercise the option, pSivida may develop the product independently or with a partner.
- Cessation of Development: If pSivida ceases development prior to Phase II completion, Pfizer has an option to acquire the license for a lesser fee, with correspondingly lower milestones and royalties for pSivida.
- Termination Risk: The agreement may be terminated for material breach or bankruptcy. Pfizer's ability to terminate at its discretion introduces uncertainty regarding the long-term partnership.
Key Facts for Investor Verification
- Verify the receipt of the $2.3 million upfront cash payment and its impact on current liquidity.
- Confirm the timeline and progress of the ongoing Phase I/II clinical study.
- Assess the probability of Pfizer exercising the $20 million option post-Phase II based on clinical data.
- Review the specific terms regarding the "lesser option fee" and reduced milestones if development is ceased early.
- Clarify the status of the intellectual property rights regained by pSivida outside the scope of the new agreement.